Check our last paper - AI-enhanced cardiac digital twins extend drug proarrhythmic risk assessment through experimental data uncertainty propagation and overdose exploration: A loperamide case study
Check our last paper - AI-enhanced cardiac digital twins extend drug proarrhythmic risk assessment through experimental data uncertainty propagation and overdose exploration: A loperamide case study
Check our last paper - AI-enhanced cardiac digital twins extend drug proarrhythmic risk assessment through experimental data uncertainty propagation and overdose exploration: A loperamide case study
Check our last paper - AI-enhanced cardiac digital twins extend drug proarrhythmic risk assessment through experimental data uncertainty propagation and overdose exploration: A loperamide case study
Check our last paper - AI-enhanced cardiac digital twins extend drug proarrhythmic risk assessment through experimental data uncertainty propagation and overdose exploration: A loperamide case study
Check our last paper - AI-enhanced cardiac digital twins extend drug proarrhythmic risk assessment through experimental data uncertainty propagation and overdose exploration: A loperamide case study
Check our last paper - AI-enhanced cardiac digital twins extend drug proarrhythmic risk assessment through experimental data uncertainty propagation and overdose exploration: A loperamide case study
Check our last paper - AI-enhanced cardiac digital twins extend drug proarrhythmic risk assessment through experimental data uncertainty propagation and overdose exploration: A loperamide case study
Go to homepage

Book your V.HEART Demo

Live platform demo

See V.HEART-Discovery and V.HEART-Trials applied to your compound and use case.

Expert guidance

Talk directly with our computational medicine scientists.

Tailored to you

Focused on your therapeutic area and development stage.

See how V.HEART fits into your cardiac safety and clinical development workflow. Tell us about your compound and use case, and our team will be in touch to explore how V.HEART-Discovery predicts human QT prolongation from ion-channel assay data, and how V.HEART-Trials simulates treatments across virtual patient populations.